✦ LIBER ✦

Cancer patterns among children of Turkish descent in Germany: A study at the German Childhood Cancer Registry

✍ Scribed by Jacob Spallek; Claudia Spix; Hajo Zeeb; Peter Kaatsch; Oliver Razum

Book ID: 115015585
Publisher: BioMed Central
Year: 2008
Tongue: English
Weight: 253 KB
Volume: 8
Category: Article
ISSN: 1471-2458
DOI: 10.1186/1471-2458-8-152

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Cancer survival among children of Turkis

Cancer survival among children of Turkish descent in Germany 1980–2005: a registry-based analysis

✍ Claudia Spix; Jacob Spallek; Peter Kaatsch; Oliver Razum; Hajo Zeeb 📂 Article 📅 2008 🏛 BioMed Central 🌐 English ⚖ 249 KB

Incidence and time trends of soft tissue

Incidence and time trends of soft tissue sarcomas in German children 1985–2004 – A report from the population-based German Childhood Cancer Registry

✍ Thomas Weihkopf; Maria Blettner; Tobias Dantonello; Irene Jung; Thomas Klingebie 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 184 KB

Expression of HOX11 in childhood T-linea

Expression of HOX11 in childhood T-lineage acute lymphoblastic leukaemia can occur in the absence of cytogenetic aberration at 10q24: a study from the Children's Cancer Group (CCG)

✍ Kees, U R; Heerema, N A; Kumar, R; Watt, P M; Baker, D L; La, M K; Uckun, F M; S 📂 Article 📅 2003 🏛 Nature Publishing Group 🌐 English ⚖ 141 KB

Determination of the maximum tolerated d

Determination of the maximum tolerated dose of idarubicin when used in a combination chemotherapy program of reinduction of childhood ALL at first marrow relapse and a preliminary assessment of toxicity compared to that of daunorubicin: A report from the childrens cancer study group

✍ Feig, Stephen A. ;Krailo, Mark D. ;Harris, Richard E. ;Baum, Edward ;Holcenberg, 📂 Article 📅 1992 🏛 John Wiley and Sons 🌐 English ⚖ 566 KB

## Abstract An escalating‐dose trial of idarubicin, used weekly for 3 doses in combination with vincristine, prednisone, and L‐asparaginase (VPLI), to reinduce remission of childhood ALL at first bone marrow relapse was conducted by the Childrens Cancer Study Group (CCSG). The maximum tolerated dos